Literature DB >> 25394786

Dopaminergic system dysfunction in recreational dexamphetamine users.

Anouk Schrantee1, Lena Václavů2, Dennis F R Heijtel2, Matthan W A Caan1, Willy Gsell3, Paul J Lucassen4, Aart J Nederveen2, Jan Booij5, Liesbeth Reneman1.   

Abstract

Dexamphetamine (dAMPH) is a stimulant drug that is widely used recreationally as well as for the treatment of attention-deficit hyperactivity disorder (ADHD). Although animal studies have shown neurotoxic effects of dAMPH on the dopaminergic system, little is known about such effects on the human brain. Here, we studied the dopaminergic system at multiple physiological levels in recreational dAMPH users and age, gender, and IQ-matched dAMPH-naïve healthy controls. We assessed baseline D2/3 receptor availability, in addition to changes in dopamine (DA) release using single-photon emission computed tomography and DA functionality using pharmacological magnetic resonance imaging, following a dAMPH challenge. Also, the subjective responses to the challenge were determined. dAMPH users displayed significantly lower striatal DA D2/3 receptor binding compared with healthy controls. In dAMPH users, we further observed a blunted DA release and DA functionality to an acute dAMPH challenge, as well as a blunted subjective response. Finally, the lower D2/3 availability, the more pleasant the dAMPH administration was experienced by control subjects, but not by dAMPH users. Thus, in agreement with preclinical studies, we show that the recreational use of dAMPH in human subjects is associated with dopaminergic system dysfunction. These findings warrant further (longitudinal) investigations and call for caution when using this drug recreationally and for ADHD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25394786      PMCID: PMC4367461          DOI: 10.1038/npp.2014.301

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  47 in total

1.  Comparison of quantitative perfusion imaging using arterial spin labeling at 1.5 and 4.0 Tesla.

Authors:  Jiongjiong Wang; David C Alsop; Lin Li; John Listerud; Julio B Gonzalez-At; Mitchell D Schnall; John A Detre
Journal:  Magn Reson Med       Date:  2002-08       Impact factor: 4.668

2.  3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics.

Authors:  Cándido Hernández-López; Magí Farré; Pere N Roset; Esther Menoyo; Nieves Pizarro; Jordi Ortuño; Marta Torrens; Jordi Camí; Rafael de La Torre
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

3.  Melatonin in concentrated ethanol and ethanol alone attenuate methamphetamine-induced dopamine depletions in C57BL/6J mice.

Authors:  L Yu; C-F G Cherng; C Chen
Journal:  J Neural Transm (Vienna)       Date:  2002-12       Impact factor: 3.575

4.  Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment.

Authors:  D P Van Kammen; D L Murphy
Journal:  Psychopharmacologia       Date:  1975-11-21

5.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.

Authors:  G Di Chiara; A Imperato
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

6.  Enhanced response to repeated d-amphetamine challenge: evidence for behavioral sensitization in humans.

Authors:  S M Strakowski; K W Sax; M J Setters; P E Keck
Journal:  Biol Psychiatry       Date:  1996-11-01       Impact factor: 13.382

7.  Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]beta-CIT SPECT study--preliminary report.

Authors:  Liesbeth Reneman; Jan Booij; Jules Lavalaye; Kora de Bruin; Johannes B Reitsma; BoudewijnW Gunning; Gerard J den Heeten; Wim van Den Brink
Journal:  Psychopharmacology (Berl)       Date:  2001-11-20       Impact factor: 4.530

8.  Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects.

Authors:  N D Volkow; G J Wang; J S Fowler; J Logan; S J Gatley; R Hitzemann; A D Chen; S L Dewey; N Pappas
Journal:  Nature       Date:  1997-04-24       Impact factor: 49.962

9.  Striatal dopamine nerve terminal markers in human, chronic methamphetamine users.

Authors:  J M Wilson; K S Kalasinsky; A I Levey; C Bergeron; G Reiber; R M Anthony; G A Schmunk; K Shannak; J W Haycock; S J Kish
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

10.  Mapping dopamine function in primates using pharmacologic magnetic resonance imaging.

Authors:  Bruce G Jenkins; Rosario Sanchez-Pernaute; Anna-Liisa Brownell; Yin-Ching Iris Chen; Ole Isacson
Journal:  J Neurosci       Date:  2004-10-27       Impact factor: 6.709

View more
  8 in total

1.  Heightened Dopaminergic Response to Amphetamine at the D3 Dopamine Receptor in Methamphetamine Users.

Authors:  Isabelle Boileau; Doris Payer; Pablo M Rusjan; Sylvain Houle; Junchao Tong; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  Neuropsychopharmacology       Date:  2016-06-29       Impact factor: 7.853

2.  Age-Dependent Effects of Methylphenidate on the Human Dopaminergic System in Young vs Adult Patients With Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.

Authors:  Anouk Schrantee; Hyke G H Tamminga; Cheima Bouziane; Marco A Bottelier; Esther E Bron; Henk-Jan M M Mutsaerts; Aeilko H Zwinderman; Inge R Groote; Serge A R B Rombouts; Ramon J L Lindauer; Stefan Klein; Wiro J Niessen; Brent C Opmeer; Frits Boer; Paul J Lucassen; Susan L Andersen; Hilde M Geurts; Liesbeth Reneman
Journal:  JAMA Psychiatry       Date:  2016-09-01       Impact factor: 21.596

3.  Striatal Dopamine Release in Response to Morphine: A [11C]Raclopride Positron Emission Tomography Study in Healthy Men.

Authors:  Primavera A Spagnolo; Alane Kimes; Melanie L Schwandt; Ehsan Shokri-Kojori; Shantalaxmi Thada; Karran A Phillips; Nancy Diazgranados; Kenzie L Preston; Peter Herscovitch; Dardo Tomasi; Vijay A Ramchandani; Markus Heilig
Journal:  Biol Psychiatry       Date:  2019-03-15       Impact factor: 13.382

Review 4.  Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-analysis.

Authors:  Abhishekh H Ashok; Yuya Mizuno; Nora D Volkow; Oliver D Howes
Journal:  JAMA Psychiatry       Date:  2017-05-01       Impact factor: 21.596

5.  Acute drug effects differentially predict desire to take dextroamphetamine again for work and recreation.

Authors:  Jennifer K Hoots; Heather E Webber; Cecilia Nunez; Jessica A Cooper; Paula Lopez-Gamundi; Victoria M Lawlor; Scott D Lane; Michael T Treadway; Margaret C Wardle
Journal:  Psychopharmacology (Berl)       Date:  2021-06-17       Impact factor: 4.415

6.  Effects of dexamphetamine-induced dopamine release on resting-state network connectivity in recreational amphetamine users and healthy controls.

Authors:  Anouk Schrantee; Bart Ferguson; Diederick Stoffers; Jan Booij; Serge Rombouts; Liesbeth Reneman
Journal:  Brain Imaging Behav       Date:  2016-06       Impact factor: 3.978

7.  Long-term effects of stimulant exposure on cerebral blood flow response to methylphenidate and behavior in attention-deficit hyperactivity disorder.

Authors:  Anouk Schrantee; C Bouziane; E E Bron; S Klein; M A Bottelier; J J S Kooij; S A R B Rombouts; L Reneman
Journal:  Brain Imaging Behav       Date:  2018-04       Impact factor: 3.978

8.  Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate.

Authors:  Anouk Schrantee; Jordi L Tremoleda; Marzena Wylezinska-Arridge; Valentine Bouet; Peter Hesseling; Gideon F Meerhoff; Kora M de Bruin; Jan Koeleman; Thomas Freret; Michel Boulouard; Emilie Desfosses; Laurent Galineau; Alessandro Gozzi; François Dauphin; Willy Gsell; Jan Booij; Paul J Lucassen; Liesbeth Reneman
Journal:  PLoS One       Date:  2017-02-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.